OXiGENE TO PARTICIPATE IN THE RODMAN AND RENSHAW TECHVEST 7TH ANNUAL HEALTHCARE CONFERENCE; COMPANY PRESENTATION TO BE AVAILABLE VIA WEBCAST.

(From Hugin)

WALTHAM, Mass. -- October 31, 2005 - OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds to treat cancer and certain ophthalmologic diseases, announced today that Frederick Driscoll, its President and Chief Executive Officer, will present at the Rodman and Renshaw Techvest 7th Annual Healthcare Conference at the New York Palace Hotel in New York, NY. Mr. Driscoll will present on November 8, 2005 at 8:40 a.m. EST. A live and archived webcast of the presentation can be accessed by visiting http://wsw.com/webcast/rrshq7/oxgn. OXiGENE joins more than 250 public and private companies invited to participate in the event. About OXiGENE, Inc. OXiGENE is an emerging pharmaceutical company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients. CONTACT: OXiGENE, Inc. Susan Hager Director of Communications 781-547-5900 shager@oxigene.com Media: Waggener Edstrom Bioscience Jenny Moede 503-443-7507 jmoede@wagged.com Investors: MacDougall BioCommunications ...